TrialCancer immunology, immunotherapy : CII2024

Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.

Shengxiang Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.